Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK8 | P49336 | 6/20 | 0.41 |
| ▸ | LPAR1 | Q92633 | 4/20 | 0.40 |
| ▸ | LPAR5 | Q9H1C0 | 4/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.40 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.38 |
| ▸ | MPO | P05164 | 1/20 | 0.38 |
| ▸ | TPO | P07202 | 1/20 | 0.38 |
| ▸ | EPX | P11678 | 1/20 | 0.38 |
| ▸ | LPO | P22079 | 1/20 | 0.38 |
| ▸ | MET | P08581 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1260519 | 0.84 | RNF4 (0.51) | CDK8PDK1 | |
| SCHEMBL1258225 | 0.84 | ALDH1A1 (0.40) | LPAR1LPAR5PDK1 | |
| SCHEMBL1258227 | 0.84 | ALDH1A1 (0.40) | LPAR1LPAR5PDK1 | |
| SCHEMBL1258201 | 0.83 | CDK8 (0.47) | CDK8 | |
| SCHEMBL1260140 | 0.80 | MET (0.38) | LPAR1LPAR5MAPK14PDK1MET | |
| SCHEMBL1259639 | 0.77 | SLC22A12 (0.47) | — | |
| SCHEMBL5157570 | 0.75 | MAPK14 (0.43) | MAPK14PDK1MET | |
| SCHEMBL12892591 | 0.74 | TP53 (0.50) | CDK8MET | |
| SCHEMBL1924545 | 0.72 | LTB4R2 (0.51) | PDK1 | |
| SCHEMBL15015162 | 0.72 | P2RX3 (0.44) | LPAR1LPAR5MET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110046169-A1 | FUSED HETEROCYCLIC DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046169-A1 | FUSED HETEROCYCLIC DERIVATIVES AND USE THEREOF | ABL1, MAP4K2, MAP3K20 | CDK8 155/4885LPAR1 2347/4885LPAR5 2176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.